May 14th 2024
The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024.
FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC
September 28th 2023Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.
FDA Approves Phentolamine Ophthalmic Solution for Pharmacologically-Induced Mydriasis
September 27th 2023According to the approval, the percentage of study eyes returning to ≤0.2 mm from baseline pupil diameter was statistically significantly greater in the phentolamine ophthalmic solution group than placebo.